BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M

BIOLIFE SOLUTIONS INC

2025-Q1 EPS reported -$0.01 revenue$23,941,000

Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
GAAP net loss from continuing ops of $0.4M vs. $3.2M loss in Q1 2024; adjusted EBITDA of $5.7M (24% of revenue).
FY 2025 revenue guidance reaffirmed at $95.5M-$99.0M, representing 16%-20% growth over 2024.
Completed acquisition of PanTHERA CryoSolutions on April 4, 2025, adding novel cryopreservation IRI technology.
Cash and marketable securities of $107.6M at quarter end; balance sheet supports organic and inorganic growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.